Fig. 4: PVTX-405 effectively degrades IKZF2, destabilizes human Tregs ex vivo, and induces the proliferation of Teff cells. | Nature Communications

Fig. 4: PVTX-405 effectively degrades IKZF2, destabilizes human Tregs ex vivo, and induces the proliferation of Teff cells.

From: Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy

Fig. 4

a IL-2 levels secreted by Jurkat cells after activation with CD3/CD28 beads at a beads-to-cell ratio of 1:4 and treatment with increasing levels of PVTX-405 or DKY709 for 24 h. Data presented as mean ± SD, with n = 3 biological replicates for each concentration. b PVTX-405 shows significantly higher potency and maximal degradation of IKZF2 compared to DKY709 after 3 and 6 h treatment in primary human Tregs ex vivo. Data presented as mean ± SD, with n = 2 biological replicates for each concentration. c Suppression of Teff proliferation by primary human Treg cells expanded in the presence of PVTX-405 or DKY709 or DMSO. Data are shown as six independent experiments/donors, with median ± interquartile range at 1:4 Treg/Teff coculture ratio. Data are normalized to the proliferation of Teff alone for each donor. *p < 0.05. Groups were compared using two-tailed paired parametric t test. Source data are provided as a Source Data file.

Back to article page